ICU Medical Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.2%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$2.2Bnext fiscal year
Monitoring Framework
Key Performance Indicators
Consolidated Organic Revenue Growth Quarterly100.0%Target: Low to mid-single-digit range
Adjusted Gross Margin Quarterly4,100.0%Target: 43% exiting 2027
Adjusted EBITDA Quarterly98.7MTarget: $400 million to $430 million for FY 2026
Watch Items
- Smiths Medical Integration and Manufacturing SynergiesTrigger: Winding down of integration costs and consolidation of manufacturing facilitiesAction: Monitor gross margin progression toward the 43% target exiting 2027 and net leverage reduction to 2.0x
- Regulatory Clearances for Next-Generation PumpsTrigger: FDA clearance for the Medfusion 5000 syringe pump and next-generation CADD ambulatory pumpAction: Track convergence of the pump portfolio onto the single LifeShield software platform to strengthen hospital value proposition
- Tariff Exposure and Macroeconomic HeadwindsTrigger: EBITDA impact from specific tariffs and restructuring costsAction: Evaluate management's cost consolidation efforts and pricing strategies to offset the projected $25 million to $30 million margin headwind
Research as of 19 Jun 2026